11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management

Brookstone Capital Management bought a new stake in Humacyte, Inc. (NASDAQ:HUMA) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,105 shares of the company’s stock, valued at approximately $56,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Private Advisor Group LLC grew its stake in shares of Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after buying an additional 6,510 shares during the period. The Manufacturers Life Insurance Company grew its position in Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after acquiring an additional 8,557 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after acquiring an additional 8,965 shares during the last quarter. XTX Topco Ltd increased its stake in Humacyte by 48.8% during the third quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock worth $185,000 after acquiring an additional 11,172 shares during the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Humacyte in the 3rd quarter worth about $75,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Price Performance

NASDAQ:HUMA opened at $4.41 on Monday. The firm has a 50-day moving average of $4.58 and a two-hundred day moving average of $5.66. The stock has a market cap of $555.04 million, a P/E ratio of -3.29 and a beta of 1.32. Humacyte, Inc. has a 1-year low of $2.53 and a 1-year high of $9.97.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HUMA. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, TD Cowen reissued a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.